Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma

Authors: Minhui Xu, Feng Xie, Guangyang Qian, Yingying Jing, Shanshan Zhang, Lu Gao, Tao Zheng, Mengchao Wu, Jiamei Yang, Lixin Wei

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The role of ductular reaction (DR) in hepatocellular carcinoma (HCC) remains to be elucidated.

Methods

In this study, we tried to uncover possible effect by correlating peritumoral DR in a necroinflammatory microenvironment with postoperative prognosis in HCC. The expression of peritumoral DR/CK19 by immunohistochemistry, necroinflammation and fibrosis were assessed from 106 patients receiving curative resection for HCC. Prognostic values for these and other clinicopathologic factors were evaluated.

Results

Peritumoral DR significantly correlated with necroinflammation (r = 0.563, p = 3.4E-10), fibrosis (r = 0.435, p = 3.1E-06), AFP level (p = 0.010), HBsAg (p = 4.9E-4), BCLC stage (p = 0.003), TNM stage (p = 0.002), multiple nodules (p = 0.004), absence of tumor capsule (p = 0.027), severe microscopic vascular invasion (p = 0.031) and early recurrence (p = 0.010). Increased DR was significantly associated with decreased RFS/OS (p = 4.8E-04 and p = 2.6E-05, respectively) in univariate analysis and were identified as an independent prognostic factor (HR = 2.380, 95% CI = 1.250-4.534, p = 0.008 for RFS; HR = 4.294, 95% CI = 2.255-8.177, p = 9.3E-6 for OS) in multivariate analysis.

Conclusions

These results suggested that peritumoral DR in a necroinflammatory microenvironment was a poor prognostic factor for HCC after resection.
Appendix
Available only for authorised users
Literature
1.
Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resec large hepatocellular carcinoma. Ann Surg. 2009, 249 (2): 195-202.CrossRefPubMed
2.
3.
Arciero CA, Sigurdson ER: Liver-directed therapies for patients with primary liver cancer and hepatic metastases. Curr Treat Options Oncol. 2006, 7 (5): 399-409.CrossRefPubMed
4.
Roskams T, Katoonizadeh A, Komuta M: Hepatic progenitor cells: an update. Clin Liver Dis. 2010, 14 (4): 705-718.CrossRefPubMed
5.
Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, Brunt EM, Crawford JM, Crosby HA, Desmet V, et al: Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004, 39 (6): 1739-1745.CrossRefPubMed
6.
Knight B, Matthews VB, Olynyk JK, Yeoh GC: Jekyll and Hyde: evolving perspectives on the function and potential of the adult liver progenitor (oval) cell. Bioessays. 2005, 27 (11): 1192-1202.CrossRefPubMed
7.
Libbrecht L, Desmet V, Van Damme B, Roskams T: The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol. 2000, 33 (1): 76-84.CrossRefPubMed
8.
Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006, 49 (2): 138-151.CrossRefPubMed
9.
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al: High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010, 59 (7): 953-962.CrossRefPubMed
10.
Roskams T: Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006, 25 (27): 3818-3822.CrossRefPubMed
11.
Roskams T, Desmet V: Ductular reaction and its diagnostic significance. Semin Diagn Pathol. 1998, 15 (4): 259-269.PubMed
12.
Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M, Sakamoto M, Theise ND, Roncalli M: Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer. 2007, 109 (5): 915-923.CrossRefPubMed
13.
Bateman AC, Hubscher SG: Cytokeratin expression as an aid to diagnosis in medical liver biopsies. Histopathology. 2010, 56 (4): 415-425.CrossRefPubMed
14.
Knight B, Matthews VB, Akhurst B, Croager EJ, Klinken E, Abraham LJ, Olynyk JK, Yeoh G: Liver inflammation and cytokine production, but not acute phase protein synthesis, accompany the adult liver progenitor (oval) cell response to chronic liver injury. Immunol Cell Biol. 2005, 83 (4): 364-374.CrossRefPubMed
15.
Freeman A, Hamid S, Morris L, Vowler S, Rushbrook S, Wight DG, Coleman N, Alexander GJ: Improved detection of hepatocyte proliferation using antibody to the pre-replication complex: an association with hepatic fibrosis and viral replication in chronic hepatitis C virus infection. J Viral Hepat. 2003, 10 (5): 345-350.CrossRefPubMed
16.
17.
Libbrecht L, Desmet V, Van Damme B, Roskams T: Deep intralobular extension of human hepatic ‘progenitor cells’ correlates with parenchymal inflammation in chronic viral hepatitis: can ‘progenitor cells’ migrate?. J Pathol. 2000, 192 (3): 373-378.CrossRefPubMed
18.
Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L: Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010, 51 (1): 154-164.CrossRefPubMed
19.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al: Histological grading and staging of chronic hepatitis. J Hepatol. 1995, 22 (6): 696-699.CrossRefPubMed
20.
Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009, 27 (28): 4709-4717.CrossRefPubMed
21.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003, 38 (2): 200-207.CrossRefPubMed
22.
23.
Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, Demetris AJ: Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology. 1998, 28 (5): 1260-1268.CrossRefPubMed
24.
Roskams TA, Libbrecht L, Desmet VJ: Progenitor cells in diseased human liver. Semin Liver Dis. 2003, 23 (4): 385-396.CrossRefPubMed
25.
Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE: Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver. Hepatology. 2007, 45 (3): 716-724.CrossRefPubMed
26.
Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M, Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M, et al: Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut. 2011, 60 (1): 108-115.CrossRefPubMed
27.
Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR: Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. 2005, 41 (4): 809-818.CrossRefPubMed
28.
Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, et al: Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007, 133 (1): 80-90.CrossRefPubMed
29.
Fabris L, Cadamuro M, Guido M, Spirli C, Fiorotto R, Colledan M, Torre G, Alberti D, Sonzogni A, Okolicsanyi L, et al: Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol. 2007, 171 (2): 641-653.CrossRefPubMedPubMedCentral
30.
Tan J, Hytiroglou P, Wieczorek R, Park YN, Thung SN, Arias B, Theise ND: Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver. 2002, 22 (5): 365-373.CrossRefPubMed
31.
Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 1996, 24 (4): 759-765.CrossRefPubMed
32.
Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE: Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003, 18 (4): 386-392.CrossRefPubMed
33.
Fausto N: Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology. 2004, 39 (6): 1477-1487.CrossRefPubMed
34.
Bird TG, Lorenzini S, Forbes SJ: Activation of stem cells in hepatic diseases. Cell Tissue Res. 2008, 331 (1): 283-300.CrossRefPubMed
35.
Kallis YN, Robson AJ, Fallowfield JA, Thomas HC, Alison MR, Wright NA, Goldin RD, Iredale JP, Forbes SJ: Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. Gut. 2011, 60 (4): 525-533.CrossRefPubMed
36.
Deng H, Wang HF, Gao YB, Jin XL, Xiao JC: Hepatic progenitor cell represents a transitioning cell population between liver epithelium and stroma. Med Hypotheses. 2011, 76 (6): 809-812.CrossRefPubMed
37.
Pritchard MT, Nagy LE: Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr-1-deficient mice. Am J Pathol. 2010, 176 (6): 2743-2752.CrossRefPubMedPubMedCentral
38.
Clouston AD, Jonsson JR, Powell EE: Hepatic progenitor cell-mediated regeneration and fibrosis: chicken or egg?. Hepatology. 2009, 49 (5): 1424-1426.CrossRefPubMed
39.
40.
Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141 (1): 39-51.CrossRefPubMed
41.
White E, Karp C, Strohecker AM, Guo Y, Mathew R: Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol. 2010, 22 (2): 212-217.CrossRefPubMedPubMedCentral
42.
43.
Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F, Wu MC, Cong WM: Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior. Ann Surg Oncol. 2011, 18 (8): 2210-2217.CrossRefPubMed
44.
Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V: Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998, 29 (3): 455-463.CrossRefPubMed
45.
Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following Resection. J Hepatol. 2011, 54 (3): 497-505.CrossRefPubMed
46.
Larue L, Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005, 24 (50): 7443-7454.CrossRefPubMed
47.
Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, Li R, Gao L, Zhao X, Wu D, et al: Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One. 2012, 7 (8): e43272-CrossRefPubMedPubMedCentral
Metadata
Title
Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma
Authors
Minhui Xu
Feng Xie
Guangyang Qian
Yingying Jing
Shanshan Zhang
Lu Gao
Tao Zheng
Mengchao Wu
Jiamei Yang
Lixin Wei
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-65

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

Research article

A case–control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer

Research article

SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells

Study protocol

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

Research article

p21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer

Research article

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits